Corrigendum: Impact of adjuvant: trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus

Front Immunol. 2023 Sep 12:14:1283355. doi: 10.3389/fimmu.2023.1283355. eCollection 2023.

¹ Structural Informatics Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
² Infectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
³ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2022.1002286.].

Keywords: MF59 adjuvant; Yamagata lineage; challenge; commercial vaccine; influenza B.